



Clinical trial results:

HEXVIX® VERUS WHITE LIGHT GUIDED TURB FOR EORTC SCORE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER FOLLOWED BY ATTENUATED INTRAVESICAL ADJUVANT CHEMOTHERAPY.

Summary

EudraCT number	2009-012275-98
Trial protocol	DE AT
Global end of trial date	30 December 2016

Results information

Result version number	v1 (current)
This version publication date	03 November 2022
First version publication date	03 November 2022
Summary attachment (see zip file)	The Helena Study (Gierth2021_Article_TheHELENASudyHexvix-TURBVsvWhi.pdf)

Trial information

Trial identification

Sponsor protocol code	HELENA
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	University Hospital Regensburg
Sponsor organisation address	Franz-Josef-Strauss-Allee 11, Regensburg, Germany, 93053
Public contact	Dr. Josef Reisinger, multi-service-monitoring, 0049 9413782498, josef.reisinger@multi-service-monitoring.de
Scientific contact	Dr. Josef Reisinger, multi-service-monitoring, 0049 9413782498, josef.reisinger@multi-service-monitoring.de

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	17 May 2021
Is this the analysis of the primary completion data?	Yes
Primary completion date	30 December 2016
Global end of trial reached?	Yes
Global end of trial date	30 December 2016
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective is to compare the recurrence-free survival in patients with intermediate risk non-muscle invasive bladder cancer undergoing Hexvix® assisted transurethral resection of the bladder (TURB) and subsequently treated with one immediate intravesical chemotherapy instillation versus standard white-light TURB and subsequently treated with immediate and maintenance intravesical chemotherapy

Protection of trial subjects:

see publication

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 July 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Austria: 28
Country: Number of subjects enrolled	Germany: 101
Worldwide total number of subjects	129
EEA total number of subjects	129

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	129
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

In total of 7 European University hospitals and tertiary medical centres, respectively (6 German and 1 Austrian) 247 patients were randomized from July 2010 to December 2016. Final analysis included 129 patients with intermediate risk non-muscle invasive bladder cancer.

Pre-assignment

Screening details:

Screening and Inclusion:

- Cystoscopy report
- Review of clinical files/history
- Clinical examination
- IV urography, ultrasound of the urinary tract or CT scan of upper urinary tract
- Blood chemistry
- Hematology
- Urine analysis and culture in case of suspected infection
- Urine pregnancy test for women of child-bearing age
- Informed consent

Period 1

Period 1 title	Overall Period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	WL-TURB

Arm description:

WL-TURB with immediate intravesical chemotherapy followed by maintenance chemotherapy

Arm type	see above
Investigational medicinal product name	Mitomycin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Injection

Dosage and administration details:

20 mg Mitomycin weekly for 6 weeks

Arm title	Hexvix Turb
------------------	-------------

Arm description:

Patients in group 2 received Hexvix® TURB with immediate intravesical chemotherapy only

Arm type	see above
No investigational medicinal product assigned in this arm	

Number of subjects in period 1	WL-TURB	Hexvix Turb
Started	62	67
Completed	62	67

Baseline characteristics

Reporting groups

Reporting group title	WL-TURB
Reporting group description:	
WL-TURB with immediate intravesical chemotherapy followed by maintenance chemotherapy	
Reporting group title	Hexvix Turb
Reporting group description:	
Patients in group 2 received Hexvix® TURB with immediate intravesical chemotherapy only	

Reporting group values	WL-TURB	Hexvix Turb	Total
Number of subjects	62	67	129
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	0	0	0
From 65-84 years	62	67	129
85 years and over	0	0	0
Gender categorical			
hier text			
Units: Subjects			
Female	13	15	28
Male	49	52	101

Subject analysis sets

Subject analysis set title	test
Subject analysis set type	Per protocol
Subject analysis set description:	
hier text	

Reporting group values	test		
Number of subjects	3		
Age categorical			
Units: Subjects			
In utero			
Preterm newborn infants (gestational age < 37 wks)			
Newborns (0-27 days)			
Infants and toddlers (28 days-23 months)			
Children (2-11 years)			
Adolescents (12-17 years)			

Adults (18-64 years)			
From 65-84 years			
85 years and over			
Gender categorical			
hier text			
Units: Subjects			
Female	2		
Male	2		

End points

End points reporting groups

Reporting group title	WL-TURB
Reporting group description: WL-TURB with immediate intravesical chemotherapy followed by maintenance chemotherapy	
Reporting group title	Hexvix Turb
Reporting group description: Patients in group 2 received Hexvix® TURB with immediate intravesical chemotherapy only	
Subject analysis set title	test
Subject analysis set type	Per protocol
Subject analysis set description: hier text	

Primary: RFS after 12 months

End point title	RFS after 12 months ^[1]
End point description:	
End point type	Primary
End point timeframe: 12 months	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: See attached document for results	

End point values	WL-TURB	Hexvix Turb		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	62	67		
Units: whole	62	67		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information^[1]

Timeframe for reporting adverse events:

A total of 37 serious adverse events (SAEs) were documented throughout the trial whereas 6 were related to study treatment.

Adverse event reporting additional description:

No differences regarding number of SAEs, relationship to study treatment, severity or outcome were found between the treatment arms.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	CTCAE
-----------------	-------

Dictionary version	3
--------------------	---

Frequency threshold for reporting non-serious adverse events: 5 %

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: See attached document for results

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
24 February 2016	<ul style="list-style-type: none">- removal of secondary endpoint: To demonstrate that Hexvix®-guided follow-up cystoscopy enhances detection of tumour recurrence as demonstrated by white-light cystoscopy followed by Hexvix®- guided cystoscopy in one patient serving as control (white-light cystoscopy) and case (Hexvix®-cystoscopy) and documentation of additional lesions visible by Hexvix®-cystoscopy in all patients regardless of treatment arm.- prolongation of inclusion period- prolongation of follow-up period

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/34002265>